Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It was good for me. I learned something new. Glad I keep holding on.
Heard a segment on MarketPlace Money Report about the difficulties communities face when rural hospitals shut down.
I know a company who could asisst with providing rural medical care.
Come back, Mik. You are missed.
No way? Should make a lot of NF sales. I loved it.
I am in. I really enjoyed the Storage Locker movie. This company has a bright future.
Did you intentionally not capitalize the N in Nazi because you feel they should not have proper noun status? Just curious.
Anyway, LOVED your post. I'm out of here until news hits. See you all then--except for maybe the demon angel.
AWESOME d5!
Flipping is easy money for some. As for me, every time I sell, a stock ends up going up 75% of the time the day after I unload.
Hmm....this co. seems worth a look.
Long live Dr. Ichim!
Journal of Translational Medicine
BioMed Central
The King is Dead, Long Live the King: Entering A New Era of Stem Cell Research and Clinical Development
Thomas Ichim, Neil H Riordan, and David F Stroncek
Additional article information
Abstract
In mid November the biopharma industry was shocked by the announcement from Geron that they were ending work on embryonic stem cell research and therapy. For more than 10 years the public image of all stem cell research has been equated with embryonic stem cells. Unfortunately, a fundamentally important medical and financial fact was being ignored: embryonic stem cell therapy is extremely immature. In parallel to efforts in embryonic stem cell research and development, scientists and physicians in the field of adult stem cells realized that the natural role of adult stem cells in the body is to promote healing and to act like endogenous "repair cells" and, as a result, numerous companies have entered the field of adult stem cell therapy with the goal of expanding numbers of adult stem cells for administration to patients with various conditions. In contrast to embryonic stem cells, which are extremely expensive and potentially dangerous, adult cell cells are inexpensive and have an excellent safety record when used in humans. Many studies are now showing that adult stem cells are practical, patient-applicable, therapeutics that are very close to being available for incorporation into the practice of medicine. These events signal the entrance of the field of stem cells into a new era: an era where hype and misinformation no longer triumph over economic and medical realities.
...From a financial perspective, major pharmaceutical companies have already placed their bets on adult stem cells, including the $1.7 Billion Mesoblast-Cephalon deal last year, the 1.3 billion dollar Osiris-Genzyme deal, and Celgene-Anthrogenesis deal several years ago.
Thus, the field of stem cells is entering a new era: an era in which companies will be judged on clinical and financial practicality, not hype and manipulation of public emotion.
Article information
J Transl Med. 2011; 9: 218.
Published online Dec 20, 2011. doi: 10.1186/1479-5876-9-218
PMCID: PMC3275507
Thomas Ichim,1 Neil H Riordan,2 and David F Stroncek3
1MediStem Inc., San Diego, CA, USA
2Aidan Foundation, Chandler, AZ, USA
3Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA
Corresponding author.
Thomas Ichim: thomas.ichim/at/gmail.com; Neil H Riordan: nhriordan/at/gmail.com; David F Stroncek: dstroncek/at/cc.nih.gov
Received December 13, 2011; Accepted December 20, 2011.
Copyright ©2011 Ichim et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article has been cited by other articles in PMC.
Articles from Journal of Translational Medicine are provided here courtesy of BioMed Central
What do you think of NXYO?
You know what--
go To Heaven/Hell!
But, that was funny right there.
Beast,
You realize Koos is the CEO of Entest--right? So, why are you pumping over there and bashing here?
Dear Dr. Koos,
I have invested in your brand of science, and I trust you, even though my account is down $400 in a few weeks. I have not sold--nor will I. I understand you may be in some kind of quiet period...or not.
I take comfort that someone will be helped by my investment--and if I lose, I can take the loss off my taxes at the same rate as a charitable deduction.
Take all the time you need to make the best product to help the most people.
Thank you,
Sage
I would assume the Yahoo poster is referring to the "association" alluded to by the CEO in the 2/11 press release. One assumes there was a likely contract of some sort--ie, you make 2000 systems, and we will pay you X dollars.
Regardless,
I think he is right. Everyone thinks this is a scam right now, I think, but Michael Dell is no dummy.
$10 future valuation is a good target. It all depends on profit margins and how well the programmers execute plans.
Oops. It was Storage 24, but felt like a war to me. That movie was intense.
Just watched Storage Wars.
Scared the ___ out of me.
Will be investing as soon as I can re-load some $$.
I just have a feeling my $60 will be golden here. 60 lottery tickets. A night out at the poker table.
Dear Lurch,
I concur with your assessment.
Thanks!
Congrats!
Wow, Green2013,
This is worth a gamble. If you're wrong, it's my fault. :)
Lost my shirt as described. This is in my IRA.
Check out Kallo Corp. KALO
Delayed filings--but with a $$$250,000,000 contract, it may be a good thing.
.0995
300 million shares
111 float
And...with three more huge contracts and profit margins of 25%' ten bucks is within the realm of reality.
Now, that, would be a good trade.
Remember, Kallo is setting up offices in 4 separate countries...for a reason.
I, for one, would like QS to tell us where, specifically.
Now, if it soared to ten bucks, that would be grand, a few hundred thousand grand.
http://www.kalloinc.ca/career_cfo.aspx
Anyone here a CFO?
Please apply.
Check out job description-- there's that nice requirement of ensuring independent auditors solve all issues to meet deadlines.
I like that.
Bought more.
Okay-
I only have 200,000 shares, so I know I am small potatoes; however, I wanted to research nore about what Bio-Matrix has going for it other than Regen--other pipelines potentials, etc. When i click on the BioMatric icon on the Regen Pharma page, I get this link:
http://bmsn.us
No wonder there isn't more buying of this stock. Somebody should fix this.
Haven't noted movement either. What is up?
I hope this stock has not been halted. I just bought 50000 more shares, so that would ruin my day...
Unless, news has arrived to confirm .008.
Flipping my coin.
Tried to buy, but Sogotrade does not recognize symbol.
Boo!
Bought BMSN instead.
So...this is good--right?
Getting excited!
C'mon- someone takeover these glasses.
Well...I did not see that coming. Might take them a little while to put together all the pluses and minuses.
Who makes a trade for $8.03?
Which one of you is manipulating down to buy more?
Cheese and Crackers!
Back in!
Let's change the world!!!
Yes!
Thanks for sharing.
I don't know, I think I am ready to jump in. I have stayed on the sidelines due to Russia's bully ingesting, but this co. just might be a life changer.
I MAY take a position here next week.
If it gets to .20 like Bear thinks it MIGHT, then count me in.